Comparison Overview

ExecuPharm

VS

Glenmark Pharmaceuticals

ExecuPharm

610 Freedom Business Center Drive, King of Prussia, 19406, US
Last Update: 2025-12-17
Between 750 and 799

ExecuPharm is the North American clinical operations business of Parexel FSP. 10+ years of Experience Meeting Client Needs 10,000+ Global Clinical Operational Specialists In Network 80% of Recruiting Staff with >15 Years of Experience Talent Acquisition, Deployment Rates, and Employee Retention above 90% Management Staff with Tangible Industry Experience Greater Than 95% Repeat Business Average Turnaround Time of 14 Days To Deploy Project Team Resources

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 297
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
2

Glenmark Pharmaceuticals

Glenmark House, B.D.Sawant Marg,, Chakala, Andheri (East), Mumbai, Maharashtra, IN, 400099
Last Update: 2025-12-17

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 14,411
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/parexelfsp.jpeg
ExecuPharm
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/glenmark-pharmaceuticals.jpeg
Glenmark Pharmaceuticals
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
ExecuPharm
100%
Compliance Rate
0/4 Standards Verified
Glenmark Pharmaceuticals
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for ExecuPharm in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Glenmark Pharmaceuticals in 2025.

Incident History — ExecuPharm (X = Date, Y = Severity)

ExecuPharm cyber incidents detection timeline including parent company and subsidiaries

Incident History — Glenmark Pharmaceuticals (X = Date, Y = Severity)

Glenmark Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/parexelfsp.jpeg
ExecuPharm
Incidents

Date Detected: 10/2025
Type:Vulnerability
Blog: Blog

Date Detected: 6/1994
Type:Ransomware
Motivation: Financial
Blog: Blog
https://images.rankiteo.com/companyimages/glenmark-pharmaceuticals.jpeg
Glenmark Pharmaceuticals
Incidents

No Incident

FAQ

Glenmark Pharmaceuticals company demonstrates a stronger AI Cybersecurity Score compared to ExecuPharm company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

ExecuPharm company has historically faced a number of disclosed cyber incidents, whereas Glenmark Pharmaceuticals company has not reported any.

In the current year, ExecuPharm company has reported more cyber incidents than Glenmark Pharmaceuticals company.

ExecuPharm company has confirmed experiencing a ransomware attack, while Glenmark Pharmaceuticals company has not reported such incidents publicly.

Neither Glenmark Pharmaceuticals company nor ExecuPharm company has reported experiencing a data breach publicly.

Neither Glenmark Pharmaceuticals company nor ExecuPharm company has reported experiencing targeted cyberattacks publicly.

ExecuPharm company has disclosed at least one vulnerability, while Glenmark Pharmaceuticals company has not reported such incidents publicly.

Neither ExecuPharm nor Glenmark Pharmaceuticals holds any compliance certifications.

Neither company holds any compliance certifications.

ExecuPharm company has more subsidiaries worldwide compared to Glenmark Pharmaceuticals company.

Glenmark Pharmaceuticals company employs more people globally than ExecuPharm company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither ExecuPharm nor Glenmark Pharmaceuticals holds SOC 2 Type 1 certification.

Neither ExecuPharm nor Glenmark Pharmaceuticals holds SOC 2 Type 2 certification.

Neither ExecuPharm nor Glenmark Pharmaceuticals holds ISO 27001 certification.

Neither ExecuPharm nor Glenmark Pharmaceuticals holds PCI DSS certification.

Neither ExecuPharm nor Glenmark Pharmaceuticals holds HIPAA certification.

Neither ExecuPharm nor Glenmark Pharmaceuticals holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

A vulnerability has been found in SeaCMS up to 13.3. The affected element is an unknown function of the file js/player/dmplayer/dmku/class/mysqli.class.php. Such manipulation of the argument page/limit leads to sql injection. The attack can be executed remotely. The exploit has been disclosed to the public and may be used.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in HappyDevs TempTool allows Stored XSS.This issue affects TempTool: from n/a through 1.3.1.

Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in Tormorten WP Microdata allows Stored XSS.This issue affects WP Microdata: from n/a through 1.0.

Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
Description

Exposure of Sensitive System Information to an Unauthorized Control Sphere vulnerability in HappyDevs TempTool allows Retrieve Embedded Sensitive Data.This issue affects TempTool: from n/a through 1.3.1.

Risk Information
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
Description

A vulnerability has been found in Tenda FH1201 1.2.0.14(408). Affected is the function sprintf of the file /goform/SetIpBind. Such manipulation of the argument page leads to stack-based buffer overflow. The attack may be performed from remote. The exploit has been disclosed to the public and may be used.

Risk Information
cvss2
Base: 9.0
Severity: LOW
AV:N/AC:L/Au:S/C:C/I:C/A:C
cvss3
Base: 8.8
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
cvss4
Base: 7.4
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X